Intellia Therapeutics Head office building

Investors
& Media

Banner Menu

Press Releases

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Read More

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Read More

Upcoming
Events

Stock Information

Minimum 15 minutes delayed. Source: LSEG